Astellas Pharma Canada, Inc. announced that XTANDI® (enzalutamide) is now funded by the Ontario Drug Benefit Program under the Exceptional Access Program for the treatment of patients with ...

FDA approved to help select patients with metastatic prostate cancer for radioligand therapy before chemotherapy.

MetasTx, LLC, a biotechnology company focused on preventing the metastasis of solid tumor cancers – like prostate, breast and ...

Imagine a drug that halts cancer without side effects or risks. That future may be a bit nearer thanks to recent research led ...

The global prostate cancer market is projected to be valued at USD 12.9 billion in 2025 and is expected to reach USD 29.2 billion by 2035, registering a CAGR of 8.5% during the forecast period, driven ...

Berlin: Bayer has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

An expert shares crucial insights on prostate cancer, highlighting key facts and preventive measures that every man over 40 ...

Take a good look in the mirror — not just at your reflection, but at what it might be telling you. That belly bulge, which ...

Alicia Morgans, MD, MPH, discusses a potentially practice-changing abstract from the 2025 American Society of Clinical ...

Lowering prescription drug costs across the board will need the help of Congress, former Norfolk School Board member Yvonne ...

In a bold step toward affordable, locally-driven cancer treatment, the Uganda Cancer Institute (UCI) has announced the ...

Sylvester researchers have become the first to look at trends in alcohol-linked cancer mortality across the U.S. Their findings, presented last month ...